A crucial leap forward in tissue – agnostic precision oncology

Amy C. Moore shared a post by Vivek Subbiah on X, adding:

“Serving on the board of the NTRKers and having published on the challenges of NTRK detection, this is a great development for the oncology community!

It will also help those with RET-driven NSCLC.”

Quoting Vivek Subbiah’s post:

“Congratulations to the Illumina team on the US FDA approval of the TruSight Oncology Comprehensive genomic profiling test.

The 500+ gene biomarker test advances access to localized precision oncology for patients.

This approval represents a crucial leap forward in tissue-agnostic precision oncology, particularly for NTRK and RET fusions Precision Medicine for the win.

With next-generation sequencing (NGS), we can now more effectively identify patients who may benefit from targeted therapies, leading to improved clinical outcomes.

Read my quote about this approval – on the press release.”

Source: Amy C. Moore/X and Vivek Subbiah/X

Amy C. Moore is the Vice President of Global Engagement and Patient Partnerships at LUNGevity Foundation. She previously served as the Director of Science & Research at the Addario Lung Cancer Medical Institute (ALCMI). She has published peer-reviewed papers on virology, cancer, and biomarker testing in NSCLC.

Dr. Moore is also an expert on COVID-19’s impact on lung cancer and serves on several advisory boards.

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer.

He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials.